PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34761117-7 2021 In this study, we administered apatinib in combination with anti-epidermal growth factor receptor (EGFR) targeted and systemic chemotherapy for the treatment of oral cancer and to achieve better disease outcomes. apatinib 31-39 epidermal growth factor receptor Homo sapiens 65-97 32351894-0 2020 Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases. apatinib 21-29 epidermal growth factor receptor Homo sapiens 66-70 34033974-0 2021 Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706). apatinib 0-8 epidermal growth factor receptor Homo sapiens 60-64 34033974-15 2021 CONCLUSIONS: Apatinib+gefitinib as first-line therapy demonstrated superior PFS in advanced EGFR-mutant NSCLC vs placebo+gefitinib. apatinib 13-21 epidermal growth factor receptor Homo sapiens 92-96 33994798-7 2021 This case showed that afatinib plus apatinib may be a promising therapy for patients with EGFR 19Del-T790M-cis-C797S mutant and HER2 amplified NSCLC. apatinib 36-44 epidermal growth factor receptor Homo sapiens 90-94 32508029-0 2020 Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. apatinib 80-88 epidermal growth factor receptor Homo sapiens 17-21 32508029-0 2020 Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. apatinib 80-88 epidermal growth factor receptor Homo sapiens 27-31 32508029-3 2020 This pilot study aims to evaluate the tolerability, pharmacokinetic profile, and antitumor activity of apatinib plus gefitinib as a therapy for EGFR-mutant advanced NSCLC. apatinib 103-111 epidermal growth factor receptor Homo sapiens 144-148 32508029-16 2020 CONCLUSION: Apatinib (500 mg) plus gefitinib (250 mg) showed a tolerable safety profile and encouraging antitumor activity for advanced EGFR-mutant NSCLC in the first-line setting. apatinib 12-20 epidermal growth factor receptor Homo sapiens 136-140 34026823-3 2021 This multicenter, retrospective study aimed to evaluate the efficacy of the combination treatment with apatinib and osimertinib in 39 patients with EGFR-mutant non-small cell lung carcinoma (NSCLC) who developed osimertinib resistance. apatinib 103-111 epidermal growth factor receptor Homo sapiens 148-152 34026823-14 2021 The combination of apatinib and osimertinib improved the ORR and the DCR of patients with osimertinib-refractory EGFR-positive NSCLC, thus making it a reasonable treatment choice after the development of osimertinib resistance. apatinib 19-27 epidermal growth factor receptor Homo sapiens 113-117 32642151-0 2020 Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial. apatinib 15-23 epidermal growth factor receptor Homo sapiens 123-127 32642151-1 2020 Background: This trial aimed to investigate the treatment response, survival profiles and treatment-related adverse events (AEs) of apatinib plus docetaxel in advanced non-squamous non-small cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR). apatinib 132-140 epidermal growth factor receptor Homo sapiens 240-272 32642151-11 2020 Conclusions: Apatinib plus docetaxel is an effective and tolerable treatment option for advanced non-squamous NSCLC with wild-type EGFR. apatinib 13-21 epidermal growth factor receptor Homo sapiens 131-135 32351894-4 2020 We report a case of EGFR wild-type and ALK-negative lung adenocarcinoma patient with multiple symptomatic BMs, who received apatinib together with brain radiation therapy. apatinib 124-132 epidermal growth factor receptor Homo sapiens 20-24 31699150-0 2019 The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706). apatinib 27-35 epidermal growth factor receptor Homo sapiens 104-108 31231786-0 2020 A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC. apatinib 34-42 epidermal growth factor receptor Homo sapiens 97-101 31231786-2 2020 This phase I study aimed to establish the feasible dose of apatinib in combination with pemetrexed plus carboplatin as first-line therapy for epidermal growth factor receptor (EGFR) and anaplasticlymphoma kinase (ALK) negative stage IV non-squamous non-small cell lung cancer (NSCLC). apatinib 59-67 epidermal growth factor receptor Homo sapiens 142-174 31231786-2 2020 This phase I study aimed to establish the feasible dose of apatinib in combination with pemetrexed plus carboplatin as first-line therapy for epidermal growth factor receptor (EGFR) and anaplasticlymphoma kinase (ALK) negative stage IV non-squamous non-small cell lung cancer (NSCLC). apatinib 59-67 epidermal growth factor receptor Homo sapiens 176-180 31918452-0 2020 Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185). apatinib 18-26 epidermal growth factor receptor Homo sapiens 96-100 31699150-4 2019 This ACTIVE study aims to assess the combination of apatinib and gefitinib as a new treatment approach for EGFR-mutant NSCLC as a first-line setting. apatinib 52-60 epidermal growth factor receptor Homo sapiens 107-111 31699150-16 2019 ANTICIPATED OUTCOMES AND SIGNIFICANCE: The present study will be the first to evaluate the efficacy and safety profile of the combination of apatinib plus gefitinib as a first-line therapy for patients with EGFR-positive advanced non-squamous NSCLC. apatinib 141-149 epidermal growth factor receptor Homo sapiens 207-211 31570733-0 2019 Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance -A Multicenter Randomized Trial. apatinib 0-17 epidermal growth factor receptor Homo sapiens 92-96 31570733-1 2019 Few pieces of evidence have been published on the use of Apatinib Mesylate (AM) against EGFR-TKI resistance in lung adenocarcinoma (LA) patients. apatinib 57-74 epidermal growth factor receptor Homo sapiens 88-92 30003733-1 2018 PURPOSE: To investigate the efficacy and safety of apatinib mesylate (AM) in treating advanced non-small cell lung cancer (aNSCLC) with wild or unknown epidermal growth factor receptor (w/nEGFR). apatinib 51-68 epidermal growth factor receptor Homo sapiens 152-184 31073278-20 2019 These data suggested that apatinib may provide a benefit to patients with acquired resistance to EGFR-TKI treatment. apatinib 26-34 epidermal growth factor receptor Homo sapiens 97-101 30344715-6 2018 The results demonstrate that apatinib significantly inhibited cell proliferation and colony formation through promoting cell apoptosis in p53- and EGFR-mutated and wild-type glioma cells. apatinib 29-37 epidermal growth factor receptor Homo sapiens 147-151 30706337-0 2019 Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial. apatinib 0-8 epidermal growth factor receptor Homo sapiens 19-23 30706337-1 2019 Background This phase I trial was primarily conducted to determine the maximum tolerated dose (MTD) of apatinib combined with docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR who have failed to first-line platinum-based chemotherapy, and to evaluate the safety and tolerability of apatinib plus docetaxel. apatinib 103-111 epidermal growth factor receptor Homo sapiens 192-196 30702616-0 2019 Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer: A case report. apatinib 12-20 epidermal growth factor receptor Homo sapiens 50-54 30608421-0 2019 Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC: A case report. apatinib 0-8 epidermal growth factor receptor Homo sapiens 14-18 30170427-0 2018 Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis. apatinib 23-31 epidermal growth factor receptor Homo sapiens 118-122 30170427-12 2018 CONCLUSION: Apatinib has promising antitumor activity and manageable toxicity profile in patients with advanced NSCLC that failed prior chemotherapy or EGFR-TKIs. apatinib 12-20 epidermal growth factor receptor Homo sapiens 152-156 30038504-3 2018 In this report, we present a 69-year-old Chinese man with locally advanced EGFR- and ALK-negative lung SCC, who received apatinib after failure of 2 treatment regimens. apatinib 121-129 epidermal growth factor receptor Homo sapiens 75-79 29740957-0 2018 EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomes. apatinib 88-96 epidermal growth factor receptor Homo sapiens 0-4 29740957-6 2018 Herein we report a case of advanced thymic squamous cell carcinoma harboring EGFR exon 20 insertion in which apatinib was administered after multi-line chemotherapy and radiotherapy and a partial response was achieved after five months of treatment. apatinib 109-117 epidermal growth factor receptor Homo sapiens 77-81 29575765-0 2018 Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation. apatinib 23-31 epidermal growth factor receptor Homo sapiens 143-147 29575765-3 2018 The aim of this study was to explore the use of apatinib combined with icotinib therapy for primary acquired resistance to icotinib in three patients with advanced pulmonary adenocarcinoma with EGFR mutations. apatinib 48-56 epidermal growth factor receptor Homo sapiens 194-198 29575765-6 2018 Combination therapy of apatinib with icotinib for primary acquired resistance to icotinib may be an option for patients with advanced pulmonary adenocarcinoma with EGFR mutations, but physicians must also be aware of the side effects caused by such therapy. apatinib 23-31 epidermal growth factor receptor Homo sapiens 164-168 28822888-0 2017 Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. apatinib 0-8 epidermal growth factor receptor Homo sapiens 41-45 29467959-0 2018 Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR. apatinib 0-8 epidermal growth factor receptor Homo sapiens 100-104 29467959-1 2018 Objectives: This study was conducted to evaluate the efficacy and safety of apatinib in advanced NSCLC patients with EGFR wild-type who have failed more than second-line chemotherapy. apatinib 76-84 epidermal growth factor receptor Homo sapiens 117-121 29467959-2 2018 Materials and Methods: We retrospectively analyzed patients with EGFR wild-type advanced NSCLC who were treated with apatinib from January 2014 to August 2016. apatinib 117-125 epidermal growth factor receptor Homo sapiens 65-69 29467959-11 2018 Conclusions: Apatinib should be recommended as a third- or further- line therapy in advanced NSCLC patients with EGFR wild-type due to its better efficacy and tolerable toxicity. apatinib 13-21 epidermal growth factor receptor Homo sapiens 113-117 28822888-4 2017 Furthermore, we retrospectively evaluated EGFR-TKI rechallenge with apatinib in 16 patients. apatinib 68-76 epidermal growth factor receptor Homo sapiens 42-46 28822888-8 2017 EGFR-TKI rechallenge with apatinib achieved a median progression-free survival of 4.60 months (95% confidence interval, 2.23-12.52 months) in the patients. apatinib 26-34 epidermal growth factor receptor Homo sapiens 0-4 28822888-9 2017 CONCLUSIONS: Apatinib significantly potentiated the antitumour effect of gefitinib in NSCLC with T790M-related EGFR-TKI resistance both in vivo and vitro. apatinib 13-21 epidermal growth factor receptor Homo sapiens 111-115 28822888-10 2017 EGFR-TKI rechallenge with apatinib might represent a new option for NSCLC with T790M or unknown resistance mechanism. apatinib 26-34 epidermal growth factor receptor Homo sapiens 0-4 28822888-0 2017 Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. apatinib 0-8 epidermal growth factor receptor Homo sapiens 86-90 28490886-0 2017 Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report. apatinib 0-8 epidermal growth factor receptor Homo sapiens 19-23 29029508-4 2017 In this study, we showed the results of apatinib as second-line to fourth-line treatment in EGFR wild-type advanced lung adenocarcinoma patients. apatinib 40-48 epidermal growth factor receptor Homo sapiens 92-96 29029508-5 2017 16 EGFR wild-type advanced lung adenocarcinoma patients were administrated apatinib (250-500 mg/d) orally. apatinib 75-83 epidermal growth factor receptor Homo sapiens 3-7 29029508-10 2017 So, apatinib might be an optional choice for post-first-line treatment of EGFR wild-type advanced lung adenocarcinoma patients. apatinib 4-12 epidermal growth factor receptor Homo sapiens 74-78 28490886-7 2017 The patient with unknown EGFR status benefited 5-month progressive free survival (PFS) from erlotinib, and then another 5.1-month PFS with combined treatment of apatinib, which suggested a new option for lung adenocarcinoma. apatinib 161-169 epidermal growth factor receptor Homo sapiens 25-29 28490886-0 2017 Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report. apatinib 0-8 epidermal growth factor receptor Homo sapiens 102-106 28176910-0 2017 Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma. apatinib 0-8 epidermal growth factor receptor Homo sapiens 40-44 28176910-4 2017 Herein, we report three cases of advanced NSCLC with epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative status, wherein the patients showed partial response to apatinib. apatinib 192-200 epidermal growth factor receptor Homo sapiens 53-85